Last reviewed · How we verify
CM4307
At a glance
| Generic name | CM4307 |
|---|---|
| Also known as | Donafenib |
| Sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer (PHASE1, PHASE2)
- Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma (PHASE1, PHASE2)
- Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer (PHASE1, PHASE2)
- Donafenib for Previously Treated Metastatic Colorectal Cancer (PHASE3)
- Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma (PHASE2, PHASE3)
- Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |